Zacks Research Has Optimistic Outlook of UTHR Q4 Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Equities research analysts at Zacks Research lifted their Q4 2024 earnings per share (EPS) estimates for shares of United Therapeutics in a research report issued on Tuesday, November 19th. Zacks Research analyst R. Department now expects that the biotechnology company will earn $6.04 per share for the quarter, up from their prior estimate of $5.40. The consensus estimate for United Therapeutics' current full-year earnings is $25.10 per share. Zacks Research also issued estimates for United Therapeutics' Q3 2025 earnings at $7.33 EPS, Q4 2025 earnings at $6.74 EPS, FY2025 earnings at $27.64 EPS, Q3 2026 earnings at $7.15 EPS and FY2026 earnings at $26.89 EPS.

UTHR has been the topic of several other research reports. Argus raised their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Thursday, October 17th. LADENBURG THALM/SH SH boosted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a "buy" rating in a research report on Thursday, October 31st. Wells Fargo & Company lifted their price target on United Therapeutics from $350.00 to $380.00 and gave the stock an "overweight" rating in a research note on Tuesday, August 20th. Finally, Jefferies Financial Group lifted their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a "buy" rating in a research note on Monday, September 23rd. One research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $370.86.

United Therapeutics Price Performance

UTHR traded up $5.25 during trading on Friday, reaching $372.61. 114,832 shares of the company's stock were exchanged, compared to its average volume of 458,354. The company's fifty day simple moving average is $364.39 and its 200-day simple moving average is $330.59. The stock has a market capitalization of $16.64 billion, a P/E ratio of 16.13, a price-to-earnings-growth ratio of 1.05 and a beta of 0.56. United Therapeutics has a 1 year low of $208.62 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The business's revenue for the quarter was up 22.9% on a year-over-year basis. During the same period in the previous year, the company earned $5.38 earnings per share.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the stock. Meiji Yasuda Asset Management Co Ltd. grew its stake in shares of United Therapeutics by 1.6% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company's stock valued at $652,000 after buying an additional 33 shares in the last quarter. Toronto Dominion Bank lifted its position in shares of United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company's stock worth $1,441,000 after purchasing an additional 37 shares in the last quarter. ClariVest Asset Management LLC boosted its stake in shares of United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. grew its holdings in United Therapeutics by 14.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company's stock valued at $109,000 after purchasing an additional 42 shares in the last quarter. Finally, First Citizens Bank & Trust Co. increased its stake in United Therapeutics by 1.8% during the 3rd quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company's stock worth $961,000 after buying an additional 48 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the company's stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now directly owns 5,783 shares in the company, valued at approximately $2,384,215.24. This represents a 3.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Michael Benkowitz sold 15,000 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $1,034,510.88. This trade represents a 85.34 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,796 shares of company stock worth $40,936,370. 11.90% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.